HYDROCORTISONE SODIUM PHOSPHATE ( DrugBank: Hydrocortisone, Phosphate )

3 diseases

ID	Disease name (Link within this page)	Number of trials
53	Sjogren syndrome	1
81	Congenital adrenal hyperplasia	1
83	Addison disease	1

53. Sjogren syndrome

Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-004929-33-AT (EUCTR)	05/12/2018	27/11/2018	Effect of Ciclosporin eyedrops on symptoms of the eye and visual quality in patients with dry eye syndrome and primary or secondary Sjögren syndrome	Effect of Ciclosporin eyedrops on ocular symptoms and optical image quality in patients with primary or secondary Sjögren syndrome	primary or secondary Sjögren Syndrome;Therapeutic area: Diseases [C] - Eye Diseases [C11]	Trade Name: Ikervis Product Name: Ikervis INN or Proposed INN: CICLOSPORIN Trade Name: Softacort Product Name: Softacort INN or Proposed INN: HYDROCORTISONE SODIUM PHOSPHATE	KH Hietzing, Department of Ophthalmology	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 4	Austria

Clinical trials : 87 / Drugs : 87 - (DrugBank : 23) / Drug target genes : 12 - Drug target pathways : 68

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-001104-37-GB (EUCTR)	06/10/2014	24/07/2014	pulses study	Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia - the pulses study	Addison's disease and Congenital Adrenal Hyperplasia MedDRA version: 17.0;Level: LLT;Classification code 10011195;Term: Cortisol;System Organ Class: 100000004848 MedDRA version: 17.0;Classification code 10020518;Term: Hydrocortisone;System Organ Class: 100000004848;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: hydrocortisone sodium phosphate Product Name: hydrocortisone sodium phosphate INN or Proposed INN: hydrocortisone sodium phosphate Trade Name: hydrocortisone Product Name: hydrocortisone INN or Proposed INN: hydrocortisone	University Hospitals Bristol NHS Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			United Kingdom

Clinical trials : 20 / Drugs : 39 - (DrugBank : 13) / Drug target genes : 6 - Drug target pathways : 18

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-001104-37-GB (EUCTR)	06/10/2014	24/07/2014	pulses study	Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia - the pulses study	Addison's disease and Congenital Adrenal Hyperplasia MedDRA version: 17.0;Level: LLT;Classification code 10011195;Term: Cortisol;System Organ Class: 100000004848 MedDRA version: 17.0;Classification code 10020518;Term: Hydrocortisone;System Organ Class: 100000004848;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: hydrocortisone sodium phosphate Product Name: hydrocortisone sodium phosphate INN or Proposed INN: hydrocortisone sodium phosphate Trade Name: hydrocortisone Product Name: hydrocortisone INN or Proposed INN: hydrocortisone	University Hospitals Bristol NHS Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			United Kingdom